Atlas Trials

The Phase I Study of SIG001 Antibody on Cancer Therapy.

Clinical trial NCT07486700 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07486700
Sponsor
Peking University
Status
NOT_YET_RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Neoplams
Start date
2026-03-01
Primary completion
2028-04-01
Enrollment
66

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.